Is Sutro Biopharma, Inc. (STRO) a Buy, Sell, or Hold?
NASDAQ : STRO
Sutro Biopharma, Inc.
$21.3 USD
-$3.74 (-14.94%)
- Volume
- 1.43M
- Average Volume
- 315.1K
- Market Capitalization
- $206.13M
- P/E Ratio
- -1.22
- Dividend Yield
- 0.00%
- Price Target
- $50.00
- Year High
- $43.85
- Year Low
- $7.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $26.35
Company Overview
NASDAQ
Jane Chung
Biotechnology
Healthcare
STRO
133
US
USD
Liquidity Metrics
-0.10
26.35
26.35
8.42
0.00
Sales & Valuation
$102.48M
4.51
-3.42
-1.42
-8.79
Profitability
-$22.49
-$191.09M
-395.25%
-395.46%
185.30%
-92.89%
P/E Metrics
-1.22
-0.04
-0.04
Analyst Price Target & Rating
$50.00
$60.00
$43.00
2/5
20 Analysts
-57.40%
Financial Health Scores
-5.79
3/9
$150.16M
$241.99M
$308.88M
-$112.82M
Key Metrics (TTM)
$182.27M
1.83
-1.72
3.12
192.77%
-64.32%
-46.89%
-62.78%
-1521 days
Company Executives
| Name | Title |
|---|---|
| Hans-Peter Gerber | Chief Scientific Officer |
| David Pauling | Chief Administrative Officer & General Counsel |
| Gregory K. Chow | Chief Financial Officer |
| Jonathan Fawcett DPHIL MBBS | VP & Head of Clinical Development |
| Regina Cheng | Vice President & Controller |
| Jane Chung | Chief Executive Officer & Director |
| James R. Swartz | Founder |
| Kari E. Leetch | Senior VP and Head of People & Culture |
| Devendra Luhar | Senior Vice President of Technical Operations |
Poll Results
No votes yet today — be the first to share your view!
About Sutro Biopharma, Inc. (NASDAQ:STRO) Stock
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the ... treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Why is Sutro Biopharma Stock Falling On Wednesday?
2026-08-12 14:04:14
Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.
2026-08-12 07:00:00
– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Second dual-payload iADC program from Sutro's platform under Astellas collaboration expected to enter the clinic in the second half of 2026 – – Strong balance sheet with $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the second quarter ended June 30, 2026 and recent business highlights.
2026-08-07 07:51:24
Wall Street analysts reshuffled their ratings on Friday with some bold calls that could move money fast, including a dramatic target cut on Trade Desk and a fresh Buy on SpaceX as markets brace for next week's inflation data.
Affinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STRO
2026-07-25 04:05:36
Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 42.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,069,519 shares of the company's stock after purchasing an additional 321,137 shares during the
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-14 16:05:00
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 – – First dual-payload iADC from Sutro's platform entered the clinic under Astellas collaboration; patient dosing underway – – Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2026 and recent business highlights.
Frequently Asked Questions
-
What is the current Sutro Biopharma, Inc. (STRO) stock price?
-
Sutro Biopharma, Inc.(NASDAQ:STRO) stock price is $21.3 in the last trading session. During the trading session, STRO stock reached the peak price of $43.85 while $7.15 was the lowest point it dropped to. The percentage change in STRO stock occurred in the recent session was --14.94% while the dollar amount for the price change in STRO stock was -$3.74.
-
STRO's industry and sector of operation?
-
The NASDAQ listed STRO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of STRO?
-
Hans-Peter Gerber | Chief Scientific Officer
David Pauling | Chief Administrative Officer & General Counsel
Gregory K. Chow | Chief Financial Officer
Jonathan Fawcett DPHIL MBBS | VP & Head of Clinical Development
Regina Cheng | Vice President & Controller -
How many employees does STRO have?
-
Number of STRO employees currently stands at 133. STRO operates from 111 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
Link for STRO official website?
-
Official Website of STRO is: https://www.sutrobio.com
-
How do I contact STRO?
-
STRO could be contacted at phone #650 881 6500 and can also be accessed through its website. STRO operates from 111 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
How many shares of STRO are traded daily?
-
The average number of STRO shares traded daily for last 3 months was 315.1K.
-
What is the market cap of STRO currently?
-
The market value of STRO currently stands at $206.13M with its latest stock price at $21.3